To date, the remarkable effectiveness of chimeric antigen receptor (CAR) T-cell therapy has been largely limited to hematologic malignancies. Blood cancer patients facing a terminal diagnosis are often willing to undergo a burdensome treatment regimen and tolerate significant side effects in exchange for a chance at long-term remission.
Sean Semple
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Sean
Contact Sean, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack